This research not only identifies CDN as a novel dual inhibitor of JAK and STAT3 but also advances the development of low-toxicity, natural product-based therapeutic strategies to overcome chemoresistance and improve CRC management outcomes. The gene discussed is NT5C; the disease is colorectal carcinoma.